Positive interim data from Innate MIS416 Phase 1/2 clinical trial for chronic progressive MS

Innate Immunotherapeutics today announced positive interim data from the company's Phase 1/2 clinical trial of MIS416 in patients with chronic progressive multiple sclerosis (MS). Results of the open-label, dose-escalation/confirmation trial showed MIS416 to be well tolerated and identified a clinical dose for further evaluation. Moreover, during the dose confirmation portion of the study, 8 of 10 patients with secondary progressive MS who were treated with MIS416 for 12 weeks showed some improvement in their MS-related signs and symptoms.

“This increasingly coherent research around symptomatic relief, especially for those with secondary progressive forms of Multiple Sclerosis, is an exciting and extremely positive move in the right direction for those with MS and their families”

"The preliminary data indicate that MIS416 was safe and well tolerated, and the MS-related clinical status assessment tools used during the study also indicate that the trial agent may have had some positive effect for many of the treated patients," said neurologist Professor Tim Anderson, M.D., co-principal investigator for the study. "For example, 50% of the study subjects showed some improvement in EDSS scores over the relatively short 12 week duration of the trial. These interim results are encouraging and merit the consideration of a randomized controlled trial in patients with secondary progressive multiple sclerosis."

Source:

 Innate Immunotherapeutics

Advertisement

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Multi-year study data shows impact of new soft contact lens to slow myopia progression in children